Eversept Partners LP Makes New $910,000 Investment in InMode Ltd. $INMD

Eversept Partners LP purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the fourth quarter, HoldingsChannel reports. The fund purchased 61,938 shares of the healthcare company’s stock, valued at approximately $910,000.

Several other institutional investors have also modified their holdings of the stock. Boothbay Fund Management LLC increased its position in shares of InMode by 72.0% during the 4th quarter. Boothbay Fund Management LLC now owns 19,152 shares of the healthcare company’s stock valued at $281,000 after purchasing an additional 8,020 shares during the last quarter. Trexquant Investment LP bought a new position in InMode during the fourth quarter valued at $724,000. Jump Financial LLC raised its stake in shares of InMode by 108.9% in the fourth quarter. Jump Financial LLC now owns 66,876 shares of the healthcare company’s stock valued at $982,000 after acquiring an additional 34,865 shares during the period. California State Teachers Retirement System lifted its holdings in shares of InMode by 12.4% in the 4th quarter. California State Teachers Retirement System now owns 60,185 shares of the healthcare company’s stock worth $884,000 after acquiring an additional 6,628 shares during the last quarter. Finally, Mangrove Partners IM LLC bought a new stake in shares of InMode in the 4th quarter worth about $436,000. 68.04% of the stock is owned by institutional investors.

InMode Stock Performance

InMode stock opened at $13.36 on Thursday. The company has a market capitalization of $846.49 million, a PE ratio of 9.82 and a beta of 1.94. The company has a 50 day moving average price of $13.91 and a 200-day moving average price of $14.15. InMode Ltd. has a fifty-two week low of $12.72 and a fifty-two week high of $16.74.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.05). The firm had revenue of $82.02 million during the quarter, compared to the consensus estimate of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $0.31 EPS.

Analyst Ratings Changes

INMD has been the topic of a number of recent analyst reports. Robert W. Baird reduced their price objective on shares of InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Barclays set a $19.00 target price on InMode and gave the company an “overweight” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.00.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.